Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FRONTIER: A Feasibility Study to Evaluate the Safety of the TheRaSphere GliOblastoma (GBM) Device iN PaTIEnts With Recurrent GBM

NCT05303467 is registered in ClinicalTrials.gov with Boston Scientific Corporation as lead sponsor.

NCT NCT05303467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05303467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FRONTIER: A Feasibility Study to Evaluate the Safety of the TheRaSphere GliOblastoma (GBM) Device iN PaTIEnts With Recurrent GBM
Lead sponsor
Boston Scientific Corporation
Phase
Phase 1
Overall status
Recruiting
Start date
July 30, 2022
Completion date
June 30, 2027
Enrollment
36 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme, recurrent glioblastoma